Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) was the recipient of some unusual options trading on Friday. Investors purchased 6,039 call options on the company. This represents an increase of approximately 3,651% compared to the typical daily volume of 161 call options.
Insider Activity
In related news, Director Janet Napolitano sold 12,190 shares of the business's stock in a transaction on Monday, September 9th. The shares were sold at an average price of $7.80, for a total value of $95,082.00. Following the completion of the sale, the director now owns 11,616 shares of the company's stock, valued at approximately $90,604.80. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 15.60% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the stock. Vanguard Group Inc. boosted its stake in shares of Vir Biotechnology by 9.8% in the fourth quarter. Vanguard Group Inc. now owns 12,297,139 shares of the company's stock valued at $123,709,000 after purchasing an additional 1,096,473 shares during the period. PNC Financial Services Group Inc. lifted its holdings in Vir Biotechnology by 20.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 11,186 shares of the company's stock worth $113,000 after buying an additional 1,869 shares during the last quarter. Hennion & Walsh Asset Management Inc. boosted its holdings in Vir Biotechnology by 14.4% in the first quarter. Hennion & Walsh Asset Management Inc. now owns 39,150 shares of the company's stock valued at $397,000 after purchasing an additional 4,917 shares in the last quarter. Nordea Investment Management AB grew its position in shares of Vir Biotechnology by 58.7% in the 1st quarter. Nordea Investment Management AB now owns 235,664 shares of the company's stock valued at $2,408,000 after buying an additional 87,190 shares during the last quarter. Finally, Texas Permanent School Fund Corp increased its position in shares of Vir Biotechnology by 1.4% during the first quarter. Texas Permanent School Fund Corp now owns 74,977 shares of the company's stock worth $760,000 after purchasing an additional 1,012 shares in the last quarter. Institutional investors and hedge funds own 65.32% of the company's stock.
Vir Biotechnology Price Performance
VIR traded up $1.77 during trading hours on Friday, reaching $9.26. The company's stock had a trading volume of 7,112,888 shares, compared to its average volume of 1,021,156. The stock has a market cap of $1.27 billion, a PE ratio of -2.30 and a beta of 0.46. Vir Biotechnology has a fifty-two week low of $7.12 and a fifty-two week high of $13.09. The business's 50-day moving average is $7.74 and its 200-day moving average is $8.86.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last posted its earnings results on Thursday, October 31st. The company reported ($1.56) EPS for the quarter, missing analysts' consensus estimates of ($0.96) by ($0.60). The business had revenue of $2.38 million during the quarter, compared to analysts' expectations of $5.54 million. Vir Biotechnology had a negative net margin of 612.40% and a negative return on equity of 30.93%. Vir Biotechnology's revenue for the quarter was down 9.8% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.22) EPS. Analysts expect that Vir Biotechnology will post -3.26 EPS for the current year.
Wall Street Analysts Forecast Growth
A number of equities research analysts have recently commented on the stock. HC Wainwright reiterated a "buy" rating and issued a $110.00 target price on shares of Vir Biotechnology in a research report on Tuesday, August 20th. Needham & Company LLC reiterated a "buy" rating and issued a $19.00 price objective on shares of Vir Biotechnology in a report on Friday. Finally, Barclays boosted their target price on Vir Biotechnology from $27.00 to $28.00 and gave the stock an "overweight" rating in a report on Friday, August 2nd. Two analysts have rated the stock with a hold rating and three have assigned a buy rating to the company's stock. According to data from MarketBeat.com, Vir Biotechnology currently has an average rating of "Moderate Buy" and a consensus price target of $36.80.
Get Our Latest Analysis on Vir Biotechnology
About Vir Biotechnology
(
Get Free Report)
Vir Biotechnology, Inc, an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV).
Featured Articles
Before you consider Vir Biotechnology, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Vir Biotechnology wasn't on the list.
While Vir Biotechnology currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
